ArticleHLA2026
Comparison of Labscan 200 and FlexMap 3D Luminex for Anti-HLA Antibodies Monitoring.
Article in HLA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The new Luminex model FlexMap 3D is progressively replacing the previous Luminex generation in HLA laboratories for the detection and identification of anti-HLA antibodies. FlexMap 3D Luminex promises a higher degree of sensitivity, which may lead to greater mean fluorescence intensities, depending on the anti-HLA beads kit supplier. Given that anti-HLA antibodies and potential donor specific antibodies monitoring rely on MFI variations, all kits routinely used and especially Single Antigen Beads assays must be compared. In the HLA Laboratory at Toulouse Hospital, we compared the two Luminex generations using LABScreen Mix, Panel Reactive Antibody and LABScreen Single Antigen from One Lambda and Lifecodes ID from Werfen suppliers. LABScreen Mix, Panel Reactive Antibodies and Single Antigen gave the same results with both Luminex platforms. It should be noted that a divider was applied to all results obtained with FlexMap 3D when using One Lambda kits, which enabled us to obtain comparable MFI. Lifecodes ID also showed a strong correlation with both Luminex instruments, but no divider was applied and higher MFI were attained on FlexMap 3D. Serial dilutions of two monoclonal antibodies also illustrated that MFI achieved with Single Antigen from Werfen on FlexMap 3D Luminex were closer to One Lambda values. All MFI obtained with One Lambda were virtually identical when using Labscan 200 or FlexMap 3D, allowing the switch to the new Luminex platform to be made without issue. MFI gained with Werfen was higher with FlexMap 3D Luminex, which increases sensitivity, and may facilitate MFI comparisons between the two suppliers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.